---
pmid: '22975381'
title: 'A "twist box" code of p53 inactivation: twist box: p53 interaction promotes
  p53 degradation.'
authors:
- Piccinin S
- Tonin E
- Sessa S
- Demontis S
- Rossi S
- Pecciarini L
- Zanatta L
- Pivetta F
- Grizzo A
- Sonego M
- Rosano C
- Dei Tos AP
- Doglioni C
- Maestro R
journal: Cancer Cell
year: '2012'
full_text_available: false
doi: 10.1016/j.ccr.2012.08.003
---

# A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation.
**Authors:** Piccinin S, Tonin E, Sessa S, Demontis S, Rossi S, Pecciarini L, Zanatta L, Pivetta F, Grizzo A, Sonego M, Rosano C, Dei Tos AP, Doglioni C, Maestro R
**Journal:** Cancer Cell (2012)
**DOI:** [10.1016/j.ccr.2012.08.003](https://doi.org/10.1016/j.ccr.2012.08.003)

## Abstract

1. Cancer Cell. 2012 Sep 11;22(3):404-15. doi: 10.1016/j.ccr.2012.08.003.

A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 
degradation.

Piccinin S(1), Tonin E, Sessa S, Demontis S, Rossi S, Pecciarini L, Zanatta L, 
Pivetta F, Grizzo A, Sonego M, Rosano C, Dei Tos AP, Doglioni C, Maestro R.

Author information:
(1)Experimental Oncology 1, CRO National Cancer Institute, Aviano 33081, Italy. 
spiccinin@cro.it

Comment in
    Cancer Cell. 2012 Sep 11;22(3):283-5. doi: 10.1016/j.ccr.2012.08.020.

Twist proteins have been shown to contribute to cancer development and 
progression by impinging on different regulatory pathways, but their mechanism 
of action is poorly defined. By investigating the role of Twist in sarcomas, we 
found that Twist1 acts as a mechanism alternative to TP53 mutation and MDM2 
overexpression to inactivate p53 in mesenchymal tumors. We provide evidence that 
Twist1 binds p53 C terminus through the Twist box. This interaction hinders key 
posttranslational modifications of p53 and facilitates its MDM2-mediated 
degradation. Our study suggests the existence of a Twist box code of p53 
inactivation and provides the proof of principle that targeting the Twist 
box:p53 interaction might offer additional avenues for cancer treatment.

Copyright © 2012 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccr.2012.08.003
PMID: 22975381 [Indexed for MEDLINE]
